EULAR Treat-to-Target Guidelines for Gout
Treat-to-target (T2T) works when they are pragmatic and conform well to daily practice.
Gout is an ideal therapeutic area where T2T could be and should be applied.
Treat-to-target (T2T) works when they are pragmatic and conform well to daily practice.
Gout is an ideal therapeutic area where T2T could be and should be applied.
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
Reuters has reported that European drugmakers have taken the tact of warning EU physician contemplating the switch from existing (originator) biologic therapy to newer, cut-rate biosimilar. Biosimilar use is widespread outside the USA.
The current JAMA has a perspective piece on the role of the oral microbiome in the pathogenesis and references a recent article by Konig et al on "Aggregatibacter actinomycetemcomitans–induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis (RA)." (Citation
Researchers from Rush University Medical Center have reported in the March 6 issue of the Journal of Clinical Investigation that engagement of the integrin CD11b with a novel compound, may improved outcomes in patients iwth systemic lupus erythematosus (SLE).
In the United States, doctor-diagnosed arthritis is a common and widespread chronic condition (1,2). Arthritis is a leading cause of disability (3) and is projected to affect 78.4 million adults by 2040.
The current issue of the Journal of the American College of Cardiology reports on the relative risk of heart failure (HF) in rheumatoid arthritis (RA) and its relation to ischemic heart disease (IHD).
The TNF inhibitor drug development trials have indirectly taught us that monoclonal antibody based TNFi was capable of retarding the recurrence of anterior uveitis (AU) in patients with ankylosing spondylitis (AS).
On the heels of the recently published EULAR recommendations for the management of pregnancy in patients with systemic lupus erythematosus (SLE) and the anti-phospholipid syndrome (APS) comes a new meta-analysis published in the Journal of Autoimmunity on pregnancy outomes in lupus.
Dr. Cush reviews the highlights and news from the past week on RheumNow.com.
Arthritis Care & Research has reported the results of a study that analyzed the perceptions and attitudes of men afflicted with rheumatoid arthritis (RA). The results are drawn from a series of focus groups involving 22 men with RA.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.